KR860006443A - 알카놀아민 유도체의 제법 - Google Patents

알카놀아민 유도체의 제법 Download PDF

Info

Publication number
KR860006443A
KR860006443A KR1019860000921A KR860000921A KR860006443A KR 860006443 A KR860006443 A KR 860006443A KR 1019860000921 A KR1019860000921 A KR 1019860000921A KR 860000921 A KR860000921 A KR 860000921A KR 860006443 A KR860006443 A KR 860006443A
Authority
KR
South Korea
Prior art keywords
alkyl
described below
following structural
ring
structural formula
Prior art date
Application number
KR1019860000921A
Other languages
English (en)
Inventor
브리안 해그리브스 로드니
Original Assignee
알란 브라이안 벡
임페리알 케미칼 인더스트리스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알란 브라이안 벡, 임페리알 케미칼 인더스트리스 피엘씨 filed Critical 알란 브라이안 벡
Publication of KR860006443A publication Critical patent/KR860006443A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

알카놀아민 유도체의 제법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. (a) 다음 구조식의 아민을
    [식중, A,R1,R2,R3,R4,X 및 Y는 하기된 바와 같다.
    다음 구조식의 에폭 사이드와,
    [식중, Ar 및 R는 하기된 바와 같다.
    P가 0일때는 다음 구조식의 할로 케톤과 반응시키고,
    HalCH2CO-Ar
    [식중, Ar은 하기된 바와 같고, Hal은 할로 게노 그룹. 얻은 아미노 케톤을 환원하고;또는
    (b)-Y-가 아미도 그룹-CONH-에 의해 차단된 알킬렌인 디하이드로피리딘을 제조하기 위해 다음 구조식의 산 또는 그것의 활성화된 유도체를
    [식중, A,R1,R2,R3,R4및 X는 하기된 바와 같다.
    다음 구조식의 아민과 반응시키고;또는
    H2N-Y2-NHCH2CHOH(CH2O)p Ar
    [식중, Ar 및 p는 하기된 바와 같고, Y1및 Y2는 -Y1-CONH-Y2에 대해 기재된 것과 동일하다.
    (c) 다음 구조식의 화합물을
    [식중, A,R1,R2,R3,R4,X 및 Y는 하기된 바와 같고, Z는 대치가능한 그룹을 의미한다.
    다음 구조식의 아민과 반응시키고;또는
    H2NCH2CHOH(CH2O)p-Ar
    [식중, Ar 및 p는 하기된 바와 같다.
    (d) 다음 구조식의 알데하이드를
    [식중, A,X,Y,Ar 및 P는 하기된 바와 같다.
    다음 구조식 아미노크로토네이트 및
    [식중, R1및 R3는 하기된 바와 같다.
    다음 구조식의 케토에시드 유도체와 반응시키는
    R4COCH2COOR2
    [식중, R2및 R4는 하기된 바와 같다.
    것으로 구성되는, 다음 구조식의 디하이드로피리딘을 제조하는 방법.
    [식중,
    R1및 R2는 같거나 다를 수 있고, 각각 C6까지의 알킬, 알케닐 또는 알콕시 일킬;
    R3및 R4는 같거나 다를 수 있고, 각각 C6까지의 알킬;
    벤젠 환 A는 치환되지 않았거나 또는 할로 게노, 시아노, 니트로, 트리플루오로메틸 및 C6까지의 알킬에서 선택된 하나 또는 그 이상의 부가 치환체를 갖거나, 또는 5-및 6-위치에 부착된=N-C-N-=치환체를 가짐
    즉, 벤조 -2,1,3-옥사디아졸 핵을 형성);
    Ar은 할로게노, 트리플루오로메틸, 하이드록시, 아미노, 니트로, 카바모일 및 시아노, 및 각각 C6까지의 알킬, 알케닐, 알콕시, 알케닐옥시, 알콕시알콕시, 알킬티오, 알카노일, 카바모일알킬, 알카노일아미 노알킬카바모일알콕시 및 알카노일아미노, 및 C10까지의 아릴알콕시에서 선택된 하나 또는 그 이상의 치환체를 가지거나 또는 치환되지 않은 페닐, 나프틸, 테트라하이드로나프틸, 인다닐 또는 인데닐; 또는
    Ar은 환은 포화되거나 또는 비포화 되었고, 환은 옥소, 할로게노, 트리플루오로메틸, 페닐 및 모폴리노, 및 각각 C6까지의 알킬 및 알콕시, 및 C12까지의 아릴알킬에서 선택된 하나 또는 그 이상의 치환체를 가지거나 또는 치환되지 않은, 산소, 질소 및 황에서 선택된 1,2 또는 3 이종원자를 포함하는 5-또는 6-원의 복소환식 환, 및 환은 벤젠 환에 융합될 수 있어 Ar은 복소환식 환 또는 융합된 벤젠 환으로 부터 나머지 분자에 결합된다;
    p는 0 또는 1;
    X는-O-또는-S-;
    Y는 산소 (-0-), 황(-S-), 이미노 및 치환된 이미노(-NR5, 여기서 R5는 수소, 각각, C10까지의 알킬 또는 알카노일, C12까지의 페닐 또는 아랄킬), 페닐렌, 치환된 페닐렌, 피리딜렌 C6까지의 사이클로 알킬렌, 1,4-피페라지네딜, 1,4-피페리디네딜 및 아미도(-CONH-또는-NHCO-)그룹에서 선택된 하나 또는 두 그룹에 의해 임의로 차단될 수 있는 각각 C2-12의 직쇄-또는 분지쇄 알킬렌 또는 알케닐렌.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860000921A 1985-02-11 1986-02-11 알카놀아민 유도체의 제법 KR860006443A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858503425A GB8503425D0 (en) 1985-02-11 1985-02-11 Alkanolamine derivatives
GB8503425 1985-02-11

Publications (1)

Publication Number Publication Date
KR860006443A true KR860006443A (ko) 1986-09-11

Family

ID=10574270

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860000921A KR860006443A (ko) 1985-02-11 1986-02-11 알카놀아민 유도체의 제법

Country Status (21)

Country Link
US (1) US4873254A (ko)
EP (1) EP0194751B1 (ko)
JP (1) JPH0819100B2 (ko)
KR (1) KR860006443A (ko)
AU (1) AU5339486A (ko)
CS (1) CS273172B2 (ko)
DD (1) DD250533A5 (ko)
DE (1) DE3684803D1 (ko)
DK (1) DK66186A (ko)
ES (2) ES8802139A1 (ko)
FI (1) FI860621A (ko)
GB (2) GB8503425D0 (ko)
GR (1) GR860369B (ko)
HU (1) HU196179B (ko)
NO (1) NO860465L (ko)
NZ (1) NZ215083A (ko)
PH (1) PH22683A (ko)
PL (2) PL153857B1 (ko)
PT (1) PT82008B (ko)
SU (1) SU1590041A3 (ko)
ZA (1) ZA86967B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6112662A (ja) * 1984-06-28 1986-01-21 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン誘導体及びその製法
US4782160A (en) * 1986-12-08 1988-11-01 Yamanouchi Pharmaceutical Co., Ltd. 1,4-dihydropyridine derivatives
GB9102031D0 (en) * 1991-01-30 1991-03-13 Fujisawa Pharmaceutical Co Dihydropyridine compounds,and process for their preparation
AU8430098A (en) * 1998-07-23 2000-02-14 Ing-Jun Chen Guaiacoxypropanolamines with alpha/beta-adrenergic blocking activity
US8076516B2 (en) 2007-11-01 2011-12-13 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2228363A1 (de) * 1972-06-10 1974-01-03 Bayer Ag 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1409865A (en) * 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4500527A (en) * 1983-06-22 1985-02-19 Usv Pharmaceutical Corporation Antihypertensive 4[(3-alkylamino-2-hydroxypropyl)-oxyiminomethyl phenyl]-1,4-dihydropyridines
JPS6112662A (ja) * 1984-06-28 1986-01-21 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン誘導体及びその製法

Also Published As

Publication number Publication date
DK66186A (da) 1986-08-12
AU5339486A (en) 1986-08-14
ZA86967B (en) 1986-11-26
US4873254A (en) 1989-10-10
HUT40415A (en) 1986-12-28
SU1590041A3 (ru) 1990-08-30
GB8602704D0 (en) 1986-03-12
PL153857B1 (en) 1991-06-28
GB8503425D0 (en) 1985-03-13
PL265252A1 (en) 1988-06-09
GR860369B (en) 1986-06-02
PH22683A (en) 1988-11-14
JPH0819100B2 (ja) 1996-02-28
EP0194751A1 (en) 1986-09-17
PL149828B1 (en) 1990-03-31
FI860621A (fi) 1986-08-12
EP0194751B1 (en) 1992-04-15
JPS61233669A (ja) 1986-10-17
CS91186A2 (en) 1990-07-12
NO860465L (no) 1986-08-12
ES551844A0 (es) 1988-04-01
DD250533A5 (de) 1987-10-14
PT82008B (pt) 1988-07-01
ES8802139A1 (es) 1988-04-01
HU196179B (en) 1988-10-28
ES557630A0 (es) 1988-07-01
PT82008A (en) 1986-03-01
DE3684803D1 (de) 1992-05-21
FI860621A0 (fi) 1986-02-11
ES8802496A1 (es) 1988-07-01
DK66186D0 (da) 1986-02-11
CS273172B2 (en) 1991-03-12
NZ215083A (en) 1989-10-27
PL257902A1 (en) 1988-03-03

Similar Documents

Publication Publication Date Title
KR870002125A (ko) 피리딘 유도체의 제조방법
FR2663633B1 (fr) Nouvelles chalcones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PT89608A (pt) Processo para a preparacao de complexos de platina (iv) e de composicoes farmaceuticas que os contem
MY102064A (en) Detection of reticulocytes
KR860006443A (ko) 알카놀아민 유도체의 제법
KR880006238A (ko) 다제내성 암세포에 대한 감수성 증강제 및 그의 제조방법
WO2001089460A3 (de) Mittel zum färben von keratinhaltigen fasern
KR900016190A (ko) 2-페닐피리딘
KR870001214A (ko) 4,7-디히드로티에노[2,3-b]피리딘 유도체의 제조방법
MX9203233A (es) Compuestos amino heterociclicos y composicion farmaceutica que los contiene.
ATE75737T1 (de) Indenothiazolderivate und verfahren zu ihrer herstellung.
KR870004038A (ko) 제초제 화합물의 제조방법
KR870000298A (ko) 심장혈관의 병 치료용 1,4-디하이드로피리딘 유도체의 제법
KR890700584A (ko) 헤테로아릴카르복시아미드 유도체 그의 제조방법 및 그것을 함유하는 의약조성물
KR900000345A (ko) 1-할로 1-아졸일에탄유도체 및 이들을 함유하는 살균제
KR880011099A (ko) 피리딘 유도체, 이의 제조방법, 이 유도체를 함유하는 간 손상치료 및 예방제, 및 이 약제를 사용하여 간 손상을 치료 및 예방하는 방법
KR840009102A (ko) 치환된 이소퀴놀린 유도체의 제조방법
KR910004573A (ko) 이미다졸 유도체, 그의 제조방법 및 그를 함유하는 항궤양제
IE812500L (en) Piperidine derivatives
DE3673744D1 (de) Dihydropyridinderivat, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzung.
KR830004209A (ko) 옥타데센산 아미드의 제법
KR870002113A (ko) 제초제의 제조 방법
KR890010125A (ko) I 이상의 트리아졸로피리미돈 라디칼을 함유하는 신규 이소인돌린안료
DE69004138D1 (de) Mit einer Cyanogruppe substituierte Nitroanilin-Farbstoffe.
IE780577L (en) Propanolamines

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL